Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Monte Rosa Therapeutics Inc (GLUE)

Monte Rosa Therapeutics Inc (GLUE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Monte Rosa Therapeutics: Q1 Earnings Snapshot

Monte Rosa Therapeutics: Q1 Earnings Snapshot

GLUE : 4.03 (-3.13%)
Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates

GLUE : 4.03 (-3.13%)
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer

GLUE : 4.03 (-3.13%)
Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs

GLUE : 4.03 (-3.13%)
Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025

GLUE : 4.03 (-3.13%)
Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

GLUE : 4.03 (-3.13%)
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025

GLUE : 4.03 (-3.13%)
Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GLUE : 4.03 (-3.13%)
Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term

Genomics companies analyze and interpret genetic information to uncover insights about genetic variations and disease mechanisms and develop tests, therapies and technologies to advance personalized medicine. Companies...

IMCR : 32.68 (+0.90%)
CRSP : 38.82 (-1.10%)
GLUE : 4.03 (-3.13%)
CSTL : 16.27 (-1.39%)
RIGL : 20.52 (+1.99%)
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors

Monte Rosa Therapeutics appointed Dr. Eric A. Hughes to its Board, enhancing R&D leadership for its molecular glue degrader pipeline.Quiver AI SummaryMonte Rosa Therapeutics, Inc. has announced the appointment...

GLUE : 4.03 (-3.13%)

Barchart Exclusives

Palo Alto’s ARR Growth Cools, But PANW Stock’s Valuation Stays Hot
Investors should weigh Palo Alto Network’s strong fundamentals against a valuation that leaves little room for error. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar